Original Article
Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries
Desenlaces reportados por los pacientes diagnosticados con AR tratados con tofacitinib o FARME biológico bajo condiciones reales en dos países de Latinoamérica
J.M. Reyesa,
, M.V. Gutierrezb, H. Madariagac, W. Oterod, R. Guzmane, J. Izquierdof, M. Abellog, P. Velezh, D. Castillof, D. Ponce de Leoni, T. Lukicj, L. Amadora
Corresponding author
a Pfizer, Bogota, Colombia
b Pfizer, Santiago, Chile
c Centro Especializado de enfermedades neoplásicas (CEEN), Arequipa, Peru
d Centro Servimed, Bucaramanga, Colombia
e Instituto de Enfermedades Autoinmunes Renato Guzmán (IDEARG), Bogota, Colombia
f Clínica del Occidente, Cali, Colombia
g Centro Integral de Reumatología Circaribe, Barranquilla, Colombia
h Centro de Investigación en Reumatología y Especialidades Médicas (CIREEM), Bogota, Colombia
i Pfizer, Lima, Peru
j Pfizer Inc, New York, USA
Ver másRead
1679
Timeswas read the article
608
Total PDF
1071
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 April | 92 | 33 | 125 |
| 2025 March | 82 | 31 | 113 |
| 2025 February | 75 | 35 | 110 |
| 2025 January | 60 | 40 | 100 |
| 2024 December | 61 | 41 | 102 |
| 2024 November | 73 | 63 | 136 |
| 2024 October | 39 | 40 | 79 |
| 2024 September | 59 | 24 | 83 |
| 2024 August | 56 | 37 | 93 |
| 2024 July | 58 | 31 | 89 |
| 2024 June | 74 | 32 | 106 |
| 2024 May | 81 | 36 | 117 |
| 2024 April | 102 | 33 | 135 |
| 2024 March | 42 | 28 | 70 |
| 2024 February | 34 | 27 | 61 |
| 2024 January | 30 | 29 | 59 |
| 2023 December | 41 | 40 | 81 |
| 2023 November | 2 | 2 | 4 |
| 2023 October | 1 | 1 | 2 |
| 2023 September | 6 | 2 | 8 |
| 2023 June | 3 | 3 | 6 |
Show all
